Solstice Advanced Materials Inc. Common Stock
SOLS
$88.60
+7.34%
Solstice Advanced Materials Inc. is a diversified specialty chemicals company, spun off from Honeywell in late 2025, that produces low global warming potential refrigerants for HVAC and automotive systems, as well as materials for construction, semiconductors, healthcare packaging, and defense. The company holds a unique market position as a pure-play specialty chemicals entity with a critical, sole-operating US uranium conversion business, positioning it as a strategic supplier in both industrial and national security sectors. The current investor narrative is heavily focused on its post-spin-off performance and growth trajectory, with recent news highlighting its inclusion among top large-cap gainers driven by strong earnings and analyst upgrades, suggesting the market is validating its standalone potential and operational momentum.…
SOLS
Solstice Advanced Materials Inc. Common Stock
$88.60
Related headlines
Investment Opinion: Should I buy SOLS Today?
Rating: Hold. The core thesis is that SOLS is a compelling but high-risk story where much of the post-spin-off optimism is already priced in, requiring flawless execution to drive further upside, while inconsistent fundamentals present a clear path to significant downside. The Hold rating is supported by a mix of positive and cautionary data points: 1) Strong price momentum (76.36% YTD gain), 2) A premium forward PE of 27.59x implying high growth expectations, 3) Plateauing quarterly revenue in the high $900 millions suggesting decelerating growth, and 4) Analyst consensus leaning bullish but based on only 4 analysts, indicating fragile sentiment. The stock trades at a Price-to-Sales ratio of 1.99x and an EV/EBITDA of 10.48x, which are not excessive for a specialty chemicals firm with unique assets, but the earnings multiple is demanding. The two biggest risks that could invalidate a Hold thesis are a breakdown in quarterly profitability (e.g., a return to net losses) or a failure to break above the $90.8 technical resistance, leading to a sharp momentum reversal. This Hold would upgrade to a Buy if the forward PE compresses below 20x on sustained earnings growth, or if revenue re-accelerates above 10% YoY with margin expansion. It would downgrade to a Sell if the debt-to-equity ratio rises above 2.0 or if the stock breaches key support and trends toward its 52-week low. Relative to its own recent valuation history (PE range of 16.63x to 47.30x) and its current growth profile, the stock is fairly valued to slightly overvalued, pricing in significant future improvement that is not yet evident in the quarterly numbers.
Sign up to view all
SOLS 12-Month Price Forecast
The outlook for SOLS is one of high uncertainty balanced by strategic potential. The stock's dramatic run appears to have priced in the successful spin-off and much of the near-term growth, leaving it vulnerable to any fundamental disappointment. The base case of consolidation is most likely, as the company needs several quarters to prove it can deliver stable earnings to justify its valuation. The stance is neutral due to the offsetting forces of powerful momentum versus unproven fundamentals. Confidence is medium because the limited analyst coverage and short trading history post-spin-off reduce predictability. The stance would upgrade to bullish on confirmation of sustained margin recovery and revenue re-acceleration. It would downgrade to bearish on a breakdown below key technical support or a return to consistent quarterly losses.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Solstice Advanced Materials Inc. Common Stock's 12-month outlook, with a consensus price target around $115.18 and implied upside of +30.0% versus the current price.
Average Target
$115.18
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$71 - $115
Analyst target range
Analyst coverage for SOLS is limited, with only 4 analysts currently providing estimates, which is typical for a recently spun-off entity. The consensus sentiment leans bullish, as evidenced by recent institutional ratings including a 'Buy' from UBS, an 'Outperform' from BMO Capital and RBC Capital, and a 'Neutral' from Mizuho. The average estimated EPS for the forward period is $3.71, with a range from $3.36 to $4.05, indicating expectations for significant profitability growth from the current trailing EPS of $0.03. The target price range is not explicitly provided in the data, but the estimated revenue range for analysts is tight, between $4.53 billion and $4.54 billion. The high end of the EPS estimate ($4.05) likely assumes successful execution on growth initiatives and margin expansion, while the low end ($3.36) may factor in potential integration challenges or macroeconomic headwinds. The recent pattern of analyst actions, including an upgrade from RBC Capital from 'Sector Perform' to 'Outperform' in January 2026, signals growing institutional confidence following the spin-off. The limited number of analysts, however, means price discovery may be less efficient and the stock could be prone to higher volatility based on individual rating changes.
Bulls vs Bears: SOLS Investment Factors
The evidence presents a balanced but tense picture. Bullish arguments are anchored in powerful price momentum, unique strategic assets, and growing analyst confidence post-spin-off. Bearish concerns center on inconsistent fundamentals—specifically volatile profitability and plateauing revenue growth—coupled with a premium valuation that leaves little room for error. Currently, the bullish side holds stronger evidence due to the overwhelming market momentum and strategic narrative, but this is largely a sentiment-driven thesis. The single most important tension is between the stock's rich valuation (32.60x trailing PE) and its inconsistent quarterly profitability. The resolution of this tension—whether SOLS can deliver stable, growing earnings to justify its multiple—will ultimately determine the investment outcome.
Bullish
- Strong Post-Spin-Off Momentum: The stock has gained 74.62% over the past six months and 76.36% YTD, significantly outperforming the S&P 500's 6.37% and 7.68% returns over the same periods, respectively. This powerful uptrend, coupled with recent inclusion among top large-cap gainers, validates the market's confidence in its standalone potential.
- Analyst Confidence and Upgrades: Analyst sentiment is bullish, with recent ratings including a 'Buy' from UBS and 'Outperform' from BMO and RBC Capital. RBC's upgrade from 'Sector Perform' to 'Outperform' in January 2026 signals growing institutional conviction following the spin-off, supporting the positive narrative.
- Unique Strategic Asset Portfolio: The company operates the sole US uranium conversion business, a critical national security asset, alongside a diversified portfolio in low-GWP refrigerants and specialty materials. This unique positioning provides strategic moats and exposure to secular growth trends in energy and sustainability.
- Solid Return on Equity: The company generates a strong Return on Equity of 16.80%, indicating efficient use of shareholder capital. This profitability metric, coupled with a positive TTM free cash flow of $41 million, suggests the underlying business can be cash-generative.
Bearish
- Inconsistent Profitability and Margins: The company swings between profitability and losses, with Q4 2025 net income of $41 million following a Q3 loss of -$35 million. Gross margin also compressed sharply from 31.99% in Q3 to 26.14% in Q4, indicating significant earnings and margin volatility that undermines predictability.
- Revenue Growth Plateauing: Revenue growth shows signs of deceleration, with Q4 2025 revenue of $987 million representing an 8.11% YoY increase but plateauing in the high $900 million range after a jump from $913 million in Q4 2024. This suggests growth is stabilizing rather than accelerating post-spin-off.
- Elevated Valuation and Leverage: The stock trades at a rich trailing PE of 32.60x and a forward PE of 27.59x, a premium that demands flawless execution. Furthermore, the debt-to-equity ratio of 1.72 indicates a leveraged capital structure, increasing financial risk if interest rates rise or earnings falter.
- Technical Overextension and Volatility: Trading at 92% of its 52-week high ($90.8), the stock shows signs of consolidation with 1-month gains of only 2.68% versus 15.83% over three months. Its high volatility is evidenced by a -17.14% maximum drawdown, suggesting significant downside risk from current elevated levels.
SOLS Technical Analysis
The stock is in a powerful, sustained uptrend, having gained 74.62% over the past six months and 76.36% year-to-date, significantly outperforming the broader market. With a current price of $86.91, it is trading at approximately 92% of its 52-week high of $90.8, indicating strong momentum but also proximity to a key resistance level that could signal either a breakout or a period of consolidation. This positioning near the highs suggests the market has priced in significant optimism, leaving limited room for error before potential overextension. Recent momentum shows a deceleration from the explosive six-month gains, with a 2.68% increase over the past month and a 15.83% gain over three months. The 1-month return of 2.68% notably underperforms the 3-month and 6-month trends, signaling a potential consolidation phase or a pause in the rally. This divergence is further evidenced by a relative strength of 4.85 versus the S&P 500's -2.17% 1-month return, indicating the stock is still holding its ground during a broader market pullback but may be losing upward steam. Key technical support is anchored at the 52-week low of $40.43, while immediate resistance sits at the 52-week high of $90.8. A decisive breakout above $90.8 would signal a continuation of the primary uptrend, whereas a failure and reversal could see a test of lower support levels. The stock exhibits high volatility, as suggested by a maximum drawdown of -17.14% within the provided data period, which investors must factor into risk management strategies, especially given its elevated price level.
Beta
—
—
Max Drawdown
-17.1%
Largest decline past year
52-Week Range
$40-$91
Price range past year
Annual Return
—
Cumulative gain past year
| Period | SOLS Return | S&P 500 |
|---|---|---|
| 1m | +5.2% | -1.3% |
| 3m | +14.3% | +14.0% |
| 6m | +82.4% | +9.5% |
| 1y | — | +20.9% |
| ytd | +79.8% | +9.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SOLS Fundamental Analysis
Revenue growth is positive but shows signs of volatility and potential deceleration; the most recent quarterly revenue (Q4 2025) was $987 million, representing an 8.11% year-over-year increase. However, this follows a quarter (Q3 2025) with revenue of $969 million and a prior strong quarter (Q2 2025) at $965 million, indicating revenue has plateaued in the high $900 million range after a jump from $913 million in Q4 2024. The trajectory suggests growth is stabilizing post-spin-off rather than accelerating, which tempers near-term hyper-growth expectations. Profitability is inconsistent, with the company swinging between profitability and losses across recent quarters. Net income for Q4 2025 was $41 million, a positive turnaround from a net loss of -$35 million in Q3 2025, but gross margin compressed to 26.14% from 31.99% in the prior quarter. The trailing twelve-month net margin is 6.10%, and the operating margin is 18.84%, indicating the business can be profitable, but margin stability is a concern as evidenced by the quarterly swings from a high of 35.34% gross margin in Q2 2025 down to 26.14%. The balance sheet shows moderate financial health with a current ratio of 1.39, indicating sufficient short-term liquidity. However, the debt-to-equity ratio is elevated at 1.72, signaling a leveraged capital structure that could increase financial risk. Return on Equity (ROE) is a strong 16.80%, suggesting efficient use of shareholder capital. Free cash flow for the TTM is reported at $41 million, a positive sign that the company is generating cash internally, though the quarterly cash flow statements show significant variability, including a period of negative free cash flow of -$131 million in Q3 2025.
Quarterly Revenue
$987000000.0B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.26%
Latest Quarter
Free Cash Flow
$41000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SOLS Overvalued?
Given that Net Income for the latest quarter is positive ($41 million), the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 32.60x and a forward PE of 27.59x, with the forward multiple being lower, implying the market expects earnings growth to continue and improve profitability over the next year. Compared to industry averages, the valuation appears rich. The stock's trailing PE of 32.60x and Price-to-Sales (PS) ratio of 1.99x are not directly compared against provided sector averages, but the EV/EBITDA of 10.48x offers a cross-check. A premium valuation is likely being assigned due to the company's unique assets (like the sole US uranium conversion business) and its post-spin-off growth narrative, though this premium requires sustained execution to justify. Historically, the stock's own valuation has expanded significantly. The current trailing PE of 32.60x is below the Q4 2025 historical PE of 47.30 but well above the Q2 2025 level of 16.63. This places the current multiple in the upper mid-range of its recent historical band, suggesting the market has already priced in a substantial portion of the post-spin-off optimism, and further multiple expansion may be limited without significant fundamental improvements.
PE
32.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -55x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are pronounced, stemming from inconsistent profitability and high leverage. The company's net income swung from a $115.5 million profit in Q2 2025 to a $35 million loss in Q3, with gross margin volatility between 26.14% and 35.34% over recent quarters. This earnings instability, combined with a debt-to-equity ratio of 1.72, creates vulnerability to operational missteps or rising interest costs. Furthermore, while TTM free cash flow is positive at $41 million, quarterly cash flow has been highly variable, including a period of negative $131 million in Q3 2025, indicating potential liquidity pressures. Market and competitive risks are elevated due to valuation compression and sector sensitivity. Trading at a forward PE of 27.59x, SOLS carries a significant growth premium that could compress if execution falters or if the market rotates away from recently spun-off, momentum-driven names. Its beta is implied to be high given a 68.25 point outperformance versus the S&P 500 over six months, suggesting it may be more volatile and sensitive to broader market pullbacks. As a chemicals company, it also faces cyclical demand risks in its end markets like construction and semiconductors. The worst-case scenario involves a simultaneous failure to stabilize margins and a broader market downturn. This could trigger a re-rating from its current premium multiple towards its historical low PE of 16.63x (seen in Q2 2025) on declining earnings, compounded by its high financial leverage. A realistic downside could see the stock retrace to its 52-week low of $40.43, representing a potential loss of approximately -53% from the current price of $86.91. This scenario would likely be catalyzed by a significant earnings miss, a guidance cut, or a loss of the bullish analyst narrative that has supported the stock's run.
FAQ
The key risks are, in order of severity: 1) Financial Risk: High leverage with a debt-to-equity ratio of 1.72 and inconsistent profitability, as seen in the Q3 2025 net loss of $35 million. 2) Operational Risk: Significant margin volatility, with gross margin compressing from 31.99% to 26.14% between Q3 and Q4 2025. 3) Valuation Risk: Trading at a premium forward PE of 27.59x after a 74.62% six-month rally, the stock is susceptible to a sharp correction if growth expectations are not met. 4) Market & Sentiment Risk: Limited analyst coverage (only 4 analysts) means price discovery is less efficient and the stock could be prone to high volatility based on individual rating changes or sector rotation.
The 12-month forecast for SOLS is defined by three scenarios with associated probabilities. The Base Case (55% probability) sees the stock trading between $75 and $95 as the company delivers modest growth in line with analyst EPS estimates of $3.71, with the stock consolidating after its major run-up. The Bull Case (25% probability) targets $100 to $115, driven by successful execution, margin expansion, and breakout above technical resistance. The Bear Case (20% probability) warns of a drop to the $40 to $60 range if operational volatility leads to earnings misses and multiple compression. The Base Case is most likely, predicated on the assumption that SOLS stabilizes its financial performance but does not significantly exceed the high expectations already embedded in its price.
SOLS appears fairly valued to slightly overvalued based on current fundamentals. Its forward PE of 27.59x is demanding for a company with volatile earnings, though it may be justified by its unique uranium business and growth narrative. Compared to its own recent history, the trailing PE of 32.60x sits in the upper mid-range of its band (16.63x to 47.30x), suggesting the market has priced in substantial improvement. The Price-to-Sales ratio of 1.99x and EV/EBITDA of 10.48x are not extreme for the specialty chemicals sector. Overall, the valuation implies the market expects SOLS to deliver on significant earnings growth and margin stabilization. Until that is proven, the stock carries a premium that leaves it vulnerable to multiple compression.
SOLS is a high-risk, high-potential reward stock that may be suitable for certain investors but is not a clear-cut good buy for everyone. For aggressive investors comfortable with volatility, the unique strategic assets and post-spin-off momentum offer appeal. However, with the stock up 76.36% YTD and trading at a forward PE of 27.59x, much of the near-term optimism is already priced in. The average analyst EPS estimate of $3.71 implies significant growth, but the company's inconsistent quarterly profitability (swinging from a $115.5M profit to a $35M loss in recent quarters) poses a major risk. It could be a good buy on a significant pullback for long-term holders, but at current levels, the risk/reward is balanced, warranting a Hold stance.
SOLS is more suitable for a medium- to long-term investment horizon rather than short-term trading. As a recently spun-off company, it needs time to establish a standalone track record, stabilize operations, and prove its growth strategy. Its high volatility (evidenced by a -17.14% max drawdown) and momentum-driven price action make it risky for short-term traders without a strong stomach for swings. The lack of a meaningful dividend (yield of 0.19%) further reduces its appeal for income-focused or short-term holders. A suggested minimum holding period is 2-3 years to allow the investment thesis—centered on leveraging unique assets and post-spin-off efficiency—to fully play out and for the company to demonstrate consistent fundamental improvement.